The effect of native vitamin D therapy on echocardiographic parameters of patients with chronic obstructive pulmonary disease and early-stage chronic kidney disease

Aim. To assess the dynamics of the main echocardiographic parameters in patients with chronic obstructive pulmonary disease (COPD) and early-stage chronic kidney disease (CKD) taking native vitamin D.

Material and methods. The study included 264 patients, which were divided into two groups: experimental group (n=135) — patients with stage 2-4 COPD (men, mean age — 72,2±3,8 years, mean disease duration — 23,1±3,4 years); control group (n=136) — patients with stage 2-4 COPD, comparable in age and sex. Patients of both groups were divided into 4 subgroups depending on forced expiratory volume in 1 second and vitamin D levels. In the experimental group, native vitamin D therapy was performed according to regimen that maintains its level >34,3 ng/ml during the year; in the control group — according to the Russian Association of Endocrinologists guidelines. Echocardiography was performed for all patients at the beginning and end of the study.

Results. In all subgroups of the experimental group, a statistically significant increase in the left ventricular ejection fraction was revealed (p<0,05); in patients with moderate COPD (GOLD 2) and vitamin D deficiency and patients with severe and very severe COPD (GOLD 3,4) and vitamin D insufficiency of the experimental group, we observed a significant decrease in the end-systolic dimension, average left atrial size and increase in stroke volume and stroke volume index, as well as normalization of the left ventricular geometry (p<0,05). In the control group after 12 months, no significant changes were detected.

Conclusion. Maintaining of vitamin D level >34,3 ng/ml for 12 months in patients with COPD and early-stage CKD was associated with a significant improvement in myocardial remodeling. This indicates an improvement in cardiovascular adaptation and function.

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease. Updated 2017 Available at: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd.

2. Bolotova EV, Dudnikova AV. Renal dysfunction in patients with chronic obstructive pulmonary disease: comorbidity issues. Мonograph. Krasnodar: Ekoinvest, 2018; 148 р. (In Russ.) ISBN: 978-94215-402-8.

3. Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol. 2017;70(2):128-34. doi:10.1016/j.jjcc.201703.001.

4. Moiseev VS, Muhin NA, Muhin AV, et al. National recommendations. Cardiovascular risk and chronic kidney disease: strategies for car-dio-nephroprotection. Clinical nephrology. 2014;2:4-29. (In Russ.)

5. Hussien NI, El-Wakeel HS, Souror SM, et al. Alleviation of cardiac mitochondrial dysfunction and oxidative stress underlies the protective effect of vitamin D in chronic stress-induced cardiac dysfunction in rats. Gen Physiol Biophys. 2019;38(1):51-61. doi:10.4149/gpb_2018036.

6. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev. 2014;72:48-54. doi:10.1111/nure.12090.

7. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;84(3 Suppl.):622-3. doi:10.1038/kisup.2012.37

8. Pigarova EA, Rozhinskaya LYa, Belaya ZHE, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of endocrinology. 2016;62(4):60-84. (In Russ.)

9. Bolotova EV, Yavlyanskaya VV, Dudnikova AV. Predicting of the risk of major cardiovascular events developing in patients with chronic obstructive pulmonary disease in combination with renal dysfunction. Cardiovascular Therapy and Prevention. 2019;18(3):75-80. (In Russ.) doi:10.15829/1728-8800-2019-3-75-80.

10. Bolotova EV, Yavlyanskaya VV. Svidetel’stvo o registracii pro-grammy dlya EVM № 2019612850. System for calculating the time to reach the target level of vitamin D in patients with chronic obstructive pulmonary disease in combination with early stages of renal dysfunction. Published 01.03.2019. RU 2019612850. (In Russ.)

11. Beveridge LA, Struthers AD, Khan F, et al. Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data. JAMA Intern Med. 2015;175(5):745-54. doi:10.1001/jamain-ternmed.2015.0237

12. Kumar V, Yadav AK, Singhal M, et al. Vascular function and chole-calciferol supplementation in CKD: A self-controlled case series. J Steroid Biochem Mol Biol. 2018 Jun;180:19-22. doi:10.1016/j.jsbmb.2018.01.001.

13. Tamayo M, Martin-Nunes L, Val-Blasco A, et al. Calcitriol, the Bioactive Metabolite of Vitamin D, Increases Ventricular K+ Currents in Isolated Mouse Cardiomyocytes. Front Physiol. 2018;9:1186. doi:10.3389/fphys.2018.01186.

14. Zittermann A, Ernst JB, Prokop S, et al. Vitamin D supplementation of 4000 I U daily and cardiac function in patients with advanced heart failure: The EVITA trial. Int J Cardiol. 2019;280:117-23. doi:10.1016/j.ijcard.2019.01.027.

15. Aghajani H, Faal M, Hosseinsabet A. Evaluation of longitudinal left ventricular function in patients with coronary artery ectasia and vitamin D deficiency by 2D speckle tracking echocardiography. Echocardiography. 2017;34(3):397-406. doi:10.1111/echo.13467.

16. Chacko SJ, Pauwaa S, Barengolts E, et al. Vitamin D Attenuates Left Atrial Volume Changes in African American Males with Obesity and Prediabetes. Echocardiography. 2016;33(5):681-5. doi:10.1111/echo.13159.